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Case Report
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We report a patient with an elevated level of
serumbetahumanchorio-gonadotrophin (13-hCG)
due to cholangiocarcinoma. This case
demonstrates the need for consideration of
diagnoses other than germ-cell tumours when a
patient presents with a raised B-hCG level.
CASE REPORT A 45-year-old man presented
initially to a surgical unit with a history of
epigastric pain radiating to the right




He was deeply icteric on examination, with
marked ascites and a four-fingerbreadth hepar
palpableintheabdomen. Hehadsinustachycardia
(rate lOObpm) and was tachypnoeic (respiratory
rate 20 breaths per minute). Decreased air entry
was noted bibasally, more marked on the right;
oxygen saturation was normal. Bilateral pitting




small soft tissue masses involving the right
anterior pleura and right lung parenchyma and
bilateralbasalpulmonarycollapse/consolidation.
Extensive lesions replaced the entire left lobe of
liver; smaller deposits in the right lobe, ascites
and a peritoneal nodule were noted.
Liverfunctiontests werederanged(bilirubin 102
umol/l (normal = 3-18 umol/l), alkaline
phosphatase (ALP) 769U/i (normal = 30-120U/1).
gammaglutaryl transferase (GGT) 235 U/I
(normal = 12-58U/1), aspartate transaminase
(AST) 139U/I (normal = 10-40 U/1, alanine
transaminase (ALT) 54 U/I (normal = 10-56U/1),
albumin 21g/l(normal = 35-50U/1),prothrombin
17.3 seconds (normal = 12-17 seconds),
coagulation otherwisenormal. Haemoglobinwas
10.9 g/dl - normochromic, normocytic, white
cell count elevated at 16.7x 109 (neutrophil
leucocytosis). Serum tumour markers showed
serumbetahumanchorio-gonadotrophin (B-hCG)
1274 IU/1, alpha- fetoprotein (AFP) 2.4 kU/l,
prostate specific antigen (PSA) 0.1 ng/ml,
carcinoembryonic antigen (CEA) <0.5 ng/rnl,
and CA 19-9 34992 IU/ml. A liver biopsy
(performed underultrasound guidance) revealed
poorly differentiated adenocarcinoma.
Immunohistochemistry of the tumour cells was
negative for CEA, AFP, B-hCG, and cytokeratin
20, positive for cytokeratin 7 and positive for
mucin. A repeat CT scan ofchest, abdomen and
pelvis suggested a lesion in the pancreatic head
with a dilated main pancreatic duct. Given the
possibilitythatthepatienthadagermcelltumour,
and considering his poor performance status he
received a single cycle of carboplatin AUC 6
using a dose based on creatinine clearance
(calculated by the Cockroft formula using ideal
body weight'). Serum CA19-9 andB-hCG levels
were repeated on several occasions - the peak
values for these were 96,000 IU/ml and 6739 IU/i
respectively two days before his death which
occurred 25 days after chemotherapy.
Postmortem examination revealed that the bulk
of the tumour was in the left lobe of the liver,
obliterating the biliary tract and directly
infiltrating the pancreas. There were metastases
to the porta hepatis, adrenal glands, kidneys,
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abdominal wall, multiple ribs and vertebrae and
multiple pulmonary infarcts. Histology was in
keepingwithanintrahepaticbileductcarcinoma,
though pancreatic carcinoma could not be
excluded.
Human chorionic gonadotrophin is produced by
syncitiotrophoblasts, andis aglycoproteinwhich
consists ofan a and aB subunit. A serumlevel of
B-hCG> 1000 pg/ml (equivalent to 9.3 IU/1) is
believed to be highly diagnostic of gonadal
(especially nonseminomatous germ cell)
tumours.2'3 Lower levels ofelevation ofthe free
B-hCG subunit (>100 pg/ml) have previously
been demonstrated in patients with gonadal and
non-gonadal tumours; in some patients (1-2%)
with nonseminomatous germ cell tumours the
free B-hCG subunit may he the only identifiable
form in the serum.4 The nongonadal tumours in
the series by Marcillac et al included bladder,
biliary, pancreatic, and cervical neoplasms.
Microparticle enzyme immunoassay was used to
measure B-hCG (i.e. free B-hCG and intact hCG)
inourcase(Axsymsystem®,Abbottlaboratories,
Illinois, USA). The degree ofelevation ofCA19-9
is consistent with the post mortem findings.
The high total B-hCG level is extremely unusual,
butmay relate to the poorly differentiated nature
of this tumour. Serum levels of B-hCG greater
than orequal to4IU/l havebeen demonstrated to
correlate with poor prognosis in patients with
gastric carcinoma, and may represent an
independent factorreflecting notjust the tumour
burden but aggressive biology.5
Raisedlevels offreeB-hCGhavealsobeenfound
to be a poor prognostic factor in advanced
colorectal cancer.6 In a small series from Japan,
patients with cancer of unknown primary origin
and female patients with peritoneal
adenocarcinomatosis withelevated13-hCG(more
than 10 IU/1) who received platinum based
chemotherapy showedhigherresponseratesthan
patients with lower values (83.3% and 80%
respectively versus 15.3%).7 Elevated
preoperative levels of free B-hCG may also
correlate with prognosis and survival in patients
with epithelial ovarian cancers.8 The method of
analysis of B-hCG is important for comparisons
between different reports as assays report either
free B-hCG or total B-hCG.
Tissue expression of 13-hCG does not always
correlate with serum expression of B3-hCG.6
Reasons for this may include a lower detection
threshold of the serum assay, and the degree of
shedding of antigen which is related to
lymphovascular invasion, basal membrane
degradation and the extracellular matrix.
Elevation of B-hCG measured in the serum can
also occurdue to heterophilic antibodies,9 andan
alternative serum assay would have been useful
to exclude this phenomenon.
Insummary, B-hCGremains avaluablemarkerin
patients withgermcelltumoursandtrophoblastic
disease. We must however, consider other
diagnoses in the setting of an elevated serum B-
hCG(even veryhighlevels as seeninourpatient)
and a tumour of unknown origin. The atypical
clinicalpresentationasagermcelltumourshould
prompt further investigations for alternative
primary tumours, although this is unlikely to
have affected the managementofthis patientdue
to his poor general condition.
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